Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: Report of six cases

Multiple Sclerosis Journal

Volumn 18, Issue 11, 2012, Pages 1636-1639

  Hakiki, Bahia ^a   Portaccio, Emilio ^a   Giannini, Marta ^a   Razzolini, Lorenzo ^a   Pastò, Luisa ^a   Amato, Maria Pia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

fingolimod; Multiple sclerosis; rebound

Indexed keywords

FINGOLIMOD; IMMUNOLOGIC FACTOR; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ANALOGS AND DERIVATIVES; DISABILITY; DISEASE COURSE; DRUG ADMINISTRATION; DRUG SUBSTITUTION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE IMAGING; TIME; TREATMENT OUTCOME;

ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868026062     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512454773     Document Type: Article

References (8)

1. Havla JB, Pellkofer HL, Meinl I, et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol. 2012 ; 69: 262-264
2. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 402-415
3. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
4. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 ; 68: 186-191
5. Fox RK, Kappos L, Cree B, et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE Study. Fifth Joint Triennial Congress of the European and Americas Committee for Treatment and Research in Multiple Sclerosis ; Amsterdam, The Netherlands ;..
6. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 ; 76: 1858-1865
7. Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008 ; 70 (13 Pt 2). 1150-1151 (Pubitemid 351464749)
8. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011 ; 69: 759-777